AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER
Feb 132018
 

IMG_8730

IMG_8729

Dr Reddy (second from left) receives the award from Dilip Shanghvi and Prof Vishwajit Nimgaonkar.

The awards were presented by Prof. Vishwajit Nimgaonkar, Professor of Psychiatry and Human Genetics at the University of Pittsburgh, USA and Mr. Dilip Shanghvi, Managing Director, Sun Pharma

 

 

str6

Sun Pharma Science Foundation recognizes Indian scientists for exemplary contribution in pharma & medical science

New Delhi – February 13, 2018: Sun Pharma Science Foundation, a non-profit organization registered under Societies Registration Act announced the Sun Pharma Science Awards to Indian Scientists for their outstanding work and exemplary contribution to medical research.

These awards are presented in two categories – The Sun Pharma Research Awards for outstanding scientists and Sun Pharma Science Scholar Awards for young researchers. The winners for both these awards are identified in two sub-categories – Medical Sciences and Pharmaceutical Sciences. An eminent jury panel comprising well-known scientists from India selected the final winners. These Awards are presented annually to Indian scientists & young researchers working in India and abroad.

The awards were presented by Prof. Vishwajit Nimgaonkar, Professor of Psychiatry and Human Genetics at the University of Pittsburgh, USA and Mr. Dilip Shanghvi, Managing Director, Sun Pharma. Sun Pharma Research Award Winners for 2016 Medical Sciences – Basic Research Award Winner Dr. Rajan Sankaranarayanan Chief Scientist CSIR-Centre for Cellular and Molecular Biology Uppal Road, Hyderabad – 500 007, India Dr. Sankaranarayanan receives this award for his outstanding contributions in the area of protein biosynthesis, by studying proofreading mechanisms using structural biology approaches.

Image result for srinivasa reddy ncl

Dr. D. Srinivasa Reddy Senior Scientist Division of Organic Chemistry CSIR-National Chemical Laboratory Dr. Homi Bhabha Road, Pune 411008, India

Dr. Reddy receives this award for his excellent work in the area of total synthesis of biologically active natural products and medicinal chemistry using “silicon incorporation approach” towards identification of lead molecules of therapeutic potential.

The research interests of his group lie in issues related to application of oriented organic synthesis, in particular total synthesis of biologically active natural products, medicinal chemistry and crop protection. This team has been credited with having accomplished total synthesis of more than 25 natural products with impressive biological activities. “Some of our recent achievements include identification of potential leads, like antibiotic compound based on hunanamycin natural product for treating food infections, anti-diabetic molecule in collaboration with an industry partner and  anti-TB compound using a strategy called ‘re-purposing of a drug scaffold’,” said Reddy.

A total of two awardees out of four were from CSIR institutes. In addition to Reddy, Rajan Shankarnarayanan, CSIR – CCMB, Hyderabad (basic sciences), also was conferred with the award. Vikram Mathews, CMC, Vellore (medical research) and Prof Ashish Suri, AIIMS, New Delhi (clinical research), were the others to receive the awards.

With more than 80 scientific publications and 35 patents, Reddy is one of the most prominent scientists in the city and has already been honoured with the Shanti Swarup Bhatnagar prize in chemical sciences. Reddy is also a nominated member of the scientific body of Indian Pharmacopoeia, government of India and was  elected as a fellow of the Telangana and Maharashtra Academies of Sciences in addition to the National Academy of Sciences, India (NASI).

About Sun Pharma Science Foundation

Sun Pharma Science Foundation is a non-profit organization registered under Societies Registration Act. It promotes scientific research in the field of Medical and Pharmaceutical Sciences in the country through encouragement and rewarding excellence in research by channelizing both national and international knowledge and expertise. The sole mission of the Foundation is “to promote Medical and Pharmaceutical Research in India by rewarding excellence and identifying sources of knowledge and expertise”. The Sun Pharma Science Foundation is an independent Society managed by an autonomous Governing Council and all the Council Members are independent and have no interest in the commercial activities of SunPharmaceutical Industries Limited. The Foundation is chaired by Prof. Virander S. Chauhan, D Phil (Oxon), J. C. Bose Fellow (DST), Distinguished Biotechnology Research Professor, International Centre for Genetic Engineering and Biotechnology, New Delhi.

///////////////////

https://www.hindustantimes.com/pune-news/pune-based-scientists-receives-sun-pharma-research-award/story-nEVQaEKGwi7rDnr65VZ38L.html

Share

Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab

 Uncategorized  Comments Off on Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab
May 052016
 

Tildrakizumab (MK-3222)

Company Merck & Co. Inc.
Description Anti-IL-23 antibody
Molecular Target Interleukin-23 (IL-23)
Mechanism of Action Antibody
Therapeutic Modality Biologic: Antibody
Latest Stage of Development Phase III
Standard Indication Psoriasis
Indication Details Treat moderate to severe chronic plaque psoriasis
Regulatory Designation
Partner Sun Pharmaceutical Industries Ltd.

 

 

 

Tildrakizumab is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.[1]

Tildrakizumab was designed to block interleukin-23, a cytokine that plays an important role in managing the immune system and autoimmune disease. Originally developed by Schering-Plough, this drug is now part of Merck‘s clinical program, following that company’s acquisition of Schering-Plough.

Sun Pharmaceutical acquired worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of U.S. $80 million. Upon product approval, Sun Pharmaceutical will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. [2]

As of March 2014, the drug was in phase III clinical trials for plaque psoriasis. The two trials will enroll a total of nearly 2000 patients, and preliminary results are expected in June, 2015. [3][4]

References

 

http://clinicaltrials.gov/ct2/show/NCT01722331?term=SCH-900222&phase=2&fund=2&rank=2

 

Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab, MK 3222

WHITEHOUSE STATION, N.J., and MUMBAI, India, Wednesday, September 17, 2014 (BUSINESS WIRE) – Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) through their respective subsidiaries, today announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment.

Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of U.S. $80 million. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory (including product approval) and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales.

“Consistent with our previously announced global initiative to sharpen our commercial and R&D focus, including prioritizing our late stage pipeline candidates, we are pleased to enter into this agreement with Sun Pharma to help realize the potential of tildrakizumab for patients with chronic plaque psoriasis,” said Iain D. Dukes, Ph.D., senior vice president, Business Development and Licensing, Merck Research Laboratories.

“Sun Pharma is very pleased to enter into this collaboration with Merck, a recognized leader in the field of inflammatory/immunology therapies, for this late-stage candidate for chronic plaque psoriasis,” said Kirti Ganorkar, senior vice president, Business Development, Sun Pharma. “This collaboration is a part of our strategy towards building our pipeline of innovative dermatology products in a market with strong growth potential.”

The transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.

About Tildrakizumab

Tildrakizumab is an investigational humanized, anti-IL-23p19 monoclonal antibody that binds specifically to IL-23p19 and is therefore designed to selectively block the cytokine IL-23. Human genetics suggest that inhibiting IL-23 is effective for treating inflammatory conditions. In clinical studies for the treatment of chronic plaque psoriasis, tildrakizumab demonstrates efficacy in blocking inflammation by blocking IL-23. Other potential indications, which may be evaluated in future, include psoriatic arthritis and Crohn’s Disease.

Further details of the Phase 3 clinical trials can be found at: http://clinicaltrials.gov

About Merck

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international specialty pharmaceutical company with over 75% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in US, India and several other markets across the world. For the year ending March 2014, overall revenues were at US$2.7 billion, of which US contributed US$1.6 billion. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex dosage forms. More information about the company can be found at www.sunpharma.com.

Tildrakizumab
Monoclonal antibody
Type ?
Source Humanized (from mouse)
Target IL23
Identifiers
CAS Number 1326244-10-3
ATC code none
ChemSpider none
Chemical data
Formula C6426H9918N1698O2000S46
Molar mass 144.4 kg/mol

///////Sun Pharma, Merck & Co. Inc, Licensing Agreement, Tildrakizumab, mk 3222

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: